Ticker LaunchCanada to US · Cross-listing
Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp., a Canada-based company, cross-listed on Nasdaq on Aug 18, 2020, registering its securities on Form 8-A12B.
Medicenna Therapeutics Corp. is an immunotherapy company developing Superkines, which are engineered versions of the cytokines IL-2, IL-4 and IL-13. Its MDNA55 candidate targets the IL4R receptor and has been tested in a Phase 2b trial in recurrent glioblastoma.
- Type
- Cross-listing
- US exchange
- Nasdaq
- Listed
- Aug 18, 2020
- Province
- Canada
- Registration form
- 8-A12B
- Security
- Common shares
- Sector
- Biotech & pharma
More on this listing for subscribers
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration (8-A12B) Aug 18, 2020
- All filings on EDGAR CIK 1807983
Other Canadian companies listing in the US
- ImmunoPrecise Antibodies Ltd.Nasdaq · Sep 16, 2020
- Nextech3D.AI Corp.Nasdaq · Sep 15, 2020
- Lightspeed Commerce Inc.NYSE · Sep 9, 2020
- Excellon Resources IncNYSE American · Sep 8, 2020
- Akumin Inc.Nasdaq · Aug 28, 2020
- Corvus Gold ULCNasdaq · Aug 10, 2020